ETOFIBRATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H18ClNO5
Molecular Weight	363.792
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(OC1=CC=C(Cl)C=C1)C(=O)OCCOC(=O)C2=CC=CN=C2

InChI

InChIKey=XXRVYAFBUDSLJX-UHFFFAOYSA-N

InChI=1S/C18H18ClNO5/c1-18(2,25-15-7-5-14(19)6-8-15)17(22)24-11-10-23-16(21)13-4-3-9-20-12-13/h3-9,12H,10-11H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C18H18ClNO5
Molecular Weight	363.792
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://hanwhapm.en.ec21.com/Lipo-Merz-retard-cap.--551243_551266.html | https://medikamio.com/de-de/medikamente/lipo-merz-retard/pil | http://www.google.com/patents/WO2003088962A1

Etofibrate is an ethylene glycol diester of clofibrate and nicotinic acid. The drug was used under the names Tricerol and Lipo-Merz, among the others, for the treatment of severe hypertriglyceridemia and mixed hyperlipidemia. The mechanism of etofibrate action implies activation of PPAR-alpha receptors.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Peroxisome proliferator-activated receptor alpha 62 Target ID: Q07869 Gene ID: 5465.0 Gene Symbol: PPARA Target Organism: Homo sapiens (Human) Sources: http://www.google.com/patents/WO2003088962A1	Agonist 2678

Conditions

Condition	Modality	Targets	Highest Phase	Product
Severe hypertriglyceridemia 1 Sources: https://hanwhapm.en.ec21.com/Lipo-Merz-retard-cap.--551243_551266.html https://medikamio.com/de-de/medikamente/lipo-merz-retard/pil	Primary		Approved 8429	LIPO-MERZ RETARD Approved Use Lipo-Merz retard is indicated as an adjuvant treatment for a diet or other non-drug therapies (eg exercise, weight loss) for the following diseases: (1) severe hypertriglyceridemia; (2) mixed hyperlipidemia.
Mixed hyperlipidemia 2 Sources: https://hanwhapm.en.ec21.com/Lipo-Merz-retard-cap.--551243_551266.html https://medikamio.com/de-de/medikamente/lipo-merz-retard/pil	Primary		Approved 8429	LIPO-MERZ RETARD Approved Use Lipo-Merz retard is indicated as an adjuvant treatment for a diet or other non-drug therapies (eg exercise, weight loss) for the following diseases: (1) severe hypertriglyceridemia; (2) mixed hyperlipidemia.

PubMed

Title	Date	PubMed
Mitochondrial myopathy--a result of clofibrate/etofibrate treatment? Case report.	1985	4072624
Studies with etofibrate in the rat. Part I: Effects on glycerol, free fatty acid and triacylglycerol metabolism.	1988 Nov 4	3179329
Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia.	2003 Sep	14520596
High performance liquid chromatographic determination of etofibrate and its hydrolysis products.	2007 Jan 4	16901673
Peroxisome proliferator activated receptors and lipoprotein metabolism.	2008	18288277
Determination of etofibrate, fenofibrate, and atorvastatin in pharmaceutical preparations and plasma using differential pulse polarographic and square wave voltammetric techniques.	2008 Sep-Oct	18980118
[Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy].	2009 Jul	19644802
Human health risk assessment of pharmaceuticals in water: issues and challenges ahead.	2010 Nov	21139869
Methods of chromatographic determination of medicines decreasing the level of cholesterol.	2010 Sep-Oct	20873411

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose is 1 sustained-release capsule (500 mg) once daily. In special cases, up to 2 sustained-release capsules can be prescribed.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:12:08 GMT 2023` Edited by `admin` on `Fri Dec 15 16:12:08 GMT 2023`
Record UNII	23TF67G79M
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ETOFIBRATE

Official Name

English

ETOFIBRATE [MART.]

Common Name

English

ETOFIBRATE [MI]

Common Name

English

Etofibrate [WHO-DD]

Common Name

English

2-HYDROXYETHYL NICOTINATE 2-(P-CHLOROPHENOXY)-2-METHYLPROPIONATE (ESTER)

Common Name

English

etofibrate [INN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QC10AB09